Day 1 – Wednesday, September 13

09:00 LSX Welcome Address

Jade Osei-Tutu, Sr. Conference Director, LSX

---

09:10 Keynote Panel: Is Data Pharma's Next Blockbuster? Big Pharma’s Global Digital Health Priorities and Strategy 

Having made their way from the basement to the executive suite, technologies like artificial intelligence (AI) and machine learning are now shaping the future of the life sciences industry – and data is the foundation that drives these technologies forward. However, without the right tools to help manage and process it, the best data in the world can quickly become useless. 

Embracing data is a crucial step on the journey to building a digitally transformed company and evolving your technology strategy across the entire life sciences lifecycle.  Solutions to good data management can help save pharmaceutical companies billions of dollars and significantly improve the time it takes to bring life-saving new drugs to market, but the industry is still fraught with questions when it comes to centralizing, standardizing, and managing data – then transforming that data into action.  

Four leaders in life science’s data transformation will discuss those questions, addressing the challenges and opportunities that come with employing data to effectively deliver on a patient-centric mission.

• As the entire industry evolves to embrace patient data, what are healthcare stakeholders getting right? What are they getting wrong? 
  
  
• What are the biggest challenges to centralizing, standardizing, and managing data? How are you tackling those challenges? 
  
  
• Where in the value chain do you see the most opportunity for digital transformation? 
  
  
• How can data-driven technologies drive therapy adoption for the right patients – or offer more meaningful support to those already on a therapy? 
  
  
• What do you see as the next frontier when it comes to data-driven solutions? What are the tools being developed right now that will transform the way we approach healthcare?  
  
  
• What role does AI play in your company’s operations? Where do you see the most potential for healthcare to benefit from the current AI tide? 

Jane Urban, VP, Head of Data, Digital & Technology for Global Medical and Commercial, Takeda
Amy West, Head of US Digital Transformation & Innovation, Novo Nordisk 
Charles Haddad, AVP/Head Product Strategy, Global Digital Health, Eli Lilly
Meghan Dierks, Chief Data Officer, Komodo Health 

 

---

9:50 Keynote Panel: Achieving Scale and Profitability in Healthtech Businesses

• What are the best strategies for scaling digital health solutions and accelerating adoption with patients & clinicians?
• Lessons on building a scalable digital health business model
• Defining clear value propositions to address customers’ unmet needs
• Unique economic/ business models to drive profitability and the benefits of multiple revenue streams for a business

Chris Wasden, Chief Strategy Officer, Twill
John Drakenberg, CEO, Alex Therapeutics
Gabriela Perez, Chief Commercial Officer, Big Health
Randall Stanicky, CFO, Click Therapeutics 

---

10:30 Morning Break

---

11:00 Panel: Overcoming the Challenges of Developing Digital Health Products-A Pharma Perspective

• Transforming how Pharma work and building a connected infrastructure (IT, data science and AI)
• Creating an ecosystem of strategic partnerships–from promising tech start-ups to world-leading academic groups
• Integrating AI, machine learning and other emerging technologies/ digital products into worldwide innovation
• Exploring how to assess value and discussing the reimbursement process of a digital health products

Amir Zur, Executive Director, Head of R&D Digital Health Products, Takeda Pharmaceuticals
Suhas Krishna, VP, Head of Product Management, Digital Health, BMS
Ofer Waks, Director, Digital Strategy and Innovation, Pfizer

---

12:00 Panel: How are New Digital Innovations Revolutionising Clinical Trials?

The era of clinical trials as we’ve known them is coming to an end. The rising costs of running a trial, coupled with the commercial risks of failure, are unsustainable. This disruptive state is driving the adoption of new technologies and catalysing the digital transformation of clinical trials.

• Discussing the need to increase the efficiency and quality of clinical trials
• Exploring the benefits of digital innovations in clinical trials
• Overview of different types of digital innovations being used in clinical trials
• Challenges and limitations of implementing digital innovations in clinical trials
• Opportunities for future advancements and growth in the field of digital innovations in clinical trials

Josh Rose, VP, Head of Clinical Trial Delivery, Site Solutions & Strategy, CVS Health

---

12:50 Lunch Break

---

13:40 Panel: Driving Greater Adoption of Digital Therapeutics into Healthcare Systems

This discussion will focus on what happens once effective DTx is solution built and clinically validated, how do we get it into the hands of those that need it the most? Hear the lessons learned from healthcare leaders on the forefront of the digital therapeutics’ revolution.

• What challenges are DTx companies facing with integration and adoption into health systems?
• Lessons learned from scaling digital health tools within large integrated delivery networks
• Maximizing your chances for success; What needs to be true for your solution, offering and value proposition?

Pierre Leurent, President, Digital Health, Aptar Pharma
Andy Molnar, CEO, Digital Therapeutics Alliance
Eddie Martucci, Founder & CEO, Akili Interactive
Jonathan Schremp, Director of Digital Health Engagement, Banner Health 

---

14:40 Creating Successful Digital Health-Pharma Partnerships and Collaborations  

• Partnering with Pharma – What are pharma looking for? 
• The need for new collaboration models  
• Overcoming roadblocks in digital health/DTx-pharma partnerships and collaborations 
• How to create a win-win between big pharma, digital health and DTx companies  
• How to implement AI, machine learning and other emerging technologies into worldwide innovation 

Ameya Phadke, Patient Non-Pharma Solutions Leader, Chiesi  
Abhishek Shah, CEO, Wellthy Therapeutics
Gregg Talbert, SVP, Head of Personalized Healthcare and Digital Partnering, Roche  
Hassan Naqvi, Head- Digital Health Partnerships, AstraZeneca 

---

15:30 Afternoon Break

---

16:00 Revolutionizing Healthcare - Exploring New Applications of AI/ML 

How are we using data technology and advanced analytics (artificial intelligence, machine learning, and deep learning) to advance our understanding of disease and deliver breakthroughs that change patients' lives?

• Overview of how AI/ML is currently being used in healthcare and the potential it holds for the future 
• Real world examples of AI/ML applications (diagnosis/ treatment, medical imaging, drug discovery etc) 
• The role of AI in digital therapeutics and how it can improve the quality of remote care programs 

Neil Sahota, United Nations Artificial Intelligence Advisor & CEO, ACSILabs
Martin Gershon, Managing Partner & CIO, Endeavor Venture Fund
 

---

16:40 Fireside Chat: Driving Growth, Innovation, and Investment in Women’s Health  

Discussing the dynamics in the Women’s Health space, drivers in the market, the vision for the growth of technology innovations in women’s health, and how do we as a sector plan to empower women globally? 

• Where are we at on the road to solving the funding, medical research, and adoption gaps in women’s health?  
• An insight into big MedTech's women’s health growth strategy  
• What are the uncracked spaces? What are the crowded spaces? 
• Going to market in the US - are there preferred enterprise routes? Is there a playbook? 

Sapna Rao, Head of Consumer Strategy for Women’s Health, Philips 
Elizabeth Bailey, Managing Director, RH Capital 

---

17:00 Panel: Playing the Long Game-Healthtech Investment, Deals and Dollars

Due to the complexities within health technology and the health system’s complex regulation, it can be argued that a truly long-term approach is required from partners and investors. Despite the dip in digital health funding in 2022, the potential for long-term success in the healthtech space remains very real with the right strategies in place. This session will discuss the growth in partnerships with venture capital firms, the changing funding environment, and what healthtech investment activity in 2023 looks like so far.

• An overview of the healthtech investment activity over the past year (investments, valuations and exit trends)
• Is the Healthtech IPO window still shut?
• A look into M&A opportunities and trends
• The importance of healthtech companies demonstrating real value, demonstrating a path to profitability and scalable unit economics
• Notable transactions and growing digital health companies in Europe and US
• What’s next for healthtech funding, finance and investment?

Robert Garber, Partner, 7wire ventures
Nathan Sundheimer, Head, US Healthcare Partnerships, Plug and Play Tech Centre
Vishal Gulati, Managing Director, Recode Ventures

---

17:40 Drinks Reception

Day 2 – Thursday, September 14

09:00 LSX Welcome Address

Jade Osei-Tutu, Sr. Conference Director, LSX

---

09:10 Keynote Presentation: Remote Monitoring and the Future of Connected Care

The pandemic underscored the need for connected healthcare, especially for patients who needed to be monitored closely in lower acuity areas of care in the hospital and at home after hospital discharge. There is a continued, growing need and market for remote care, particularly for patients who are transitioning from higher to lower acuity settings and home. The current Medtronic Patient Monitoring business, with a portfolio of hundreds of products and $1.4B in annual revenue, is helping drive development of innovative solutions that improve patient outcomes, reduce healthcare costs, and expand patient access to care–both in and out of the hospital. With the help of advanced technology, remote patient monitoring technologies aim to support patients where they have typically not been well-monitored in low acuity areas of care in the hospital and after they are discharged from the hospital, while also alerting providers to potentially critical changes in their patients' health.

Frank Chan, President, Patient Monitoring, Medtronic

---

09:30 Panel: Making sense of device data: Helping clinicians take action with their patients

The sophistication of today's patient monitoring technologies has allowed healthcare providers to gain new insights into a patient's condition. While this information has been a game-changer in patient care, the burden of multiple datasets from different sources can cause confusion and can overwhelm providers. How can device makers and digital health companies leverage the power of electronic health records (EHRs) (interconnectivity) and AI to make sense of this information and make it more actionable for clinicians?

Frank Chan, President, Patient Monitoring, Medtronic
Russ Johannesson, CEO, Glooko
Nick Wilson, General Manager, Ambulatory Virtual Care, Philips 

---

10:30 Morning Break

---

11:10 Panel: Value-Based Care and the Future of Health

• Discussing why shifting the incentive from volume to quality of care and value for patients is the future for providers, patients and society at large
• Exploring how digital health start-ups play a role in this system, alongside incumbents, to drive up quality and specificity of care, and drive down user friction
• How is value-based care crucial to addressing inequities and inefficiencies in the healthcare system?

Corbin Petro, CEO & Co-Founder, Eleanor Health 
Jeffrey Scott, President & Chief Medical Officer, Integra Connect 
Randy Hawkins, Chief Medical Officer, Transcarent

---

11:50 Panel: Moving Mental Health into the Mainstream-Scaling Behavioural Healthtech

• What are the key challenges in scaling mental health start-ups?
• Creating a sustainable business model for mental healthtech
• Navigating the regulatory landscape for behavioural healthtech products and services
• Maximising the potential of strategic partnerships for scaling mental health innovations
• Exploring evidence-based approaches to mental healthtech innovation

Aike Ho, Partner, ACME Capital
Satish Singh, Associate Director of Strategic Partnerships, Biogen 
Enrico Picozza,Partner, HLM 
Laura Veroneau, Managing Partner, Optum Ventures 
Nawal Roy, Founder & CEO, Holmusk

---

12:50 Lunch Break

---

14:00 Panel: Unlocking the Potential of Real-World Evidence and Real-World Data in Healthcare

• Understanding the key challenges hindering the integration of real-world evidence (RWE) and real-world data (RWD) into healthcare
• How can we overcome the main barriers to RWE/RWD use? (data quality, privacy and regulatory issues)
• Connecting real world data to clinical trial data
• Discussing the opportunities that RWE/RWD can bring to healthcare (more personalized treatments, improved patient outcomes and reduced costs)
• Examining case studies of successful RWE/RWD integration in healthcare

Akshay Vashist, Head of Medical and Real-World Data Analytics, Otsuka Pharmaceutical
Sujay Jadhav, CEO, Verana Health

Danielle Jeddah, Director of Clinical Development, Healthy.io 

---

14:40 Panel: Best Practice when Launching and Running a Digital Therapeutic Clinical Trial

• Outlining best practices for digital therapeutics clinical trials and randomised controlled trials (RCTs)
• What are your options when running a clinical trial and are decentralized trials the next best thing?
• How can you generate high quality RWE with your digital therapeutic and how can you demonstrate value?
• What evidence is considered ‘good’ from a digital therapeutic clinical trial and how can you best present these for both reimbursement and regulatory approval?

Alankar Gupta, VP, Clinical Development & Medical Affairs, Click Therapeutics
Jessica Lake, Chief Science Officer, Limbix 

---

15:20 Panel: The CVC Playbook-Where are CVCs Placing their Bets?

• Understanding what CVCs are looking for in when looking to invest in digital health innovators
• What factors are driving your investment decisions, and which areas are primed for growth?
• How do you strike a balance between strategic and financial interests?
• Assessing the current valuation environment

Cris De Luca, Partner, Digital Investments, Sanofi Ventures
Dave Schulte, SVP & Managing Director, McKesson Ventures
Vijay Jun Patel, Co-Founder & Managing Partner, CVS Health Ventures 
Richard Wilmot, Global Head, Philips Ventures
Chevon Rariy, Venture Partner, Takeda Digital Ventures

---

16:00 Close of Congress